Concord Drugs Q1 Results: Net profit surges 901% YoY to ₹1.11 crore

2 min read | Published on 11 Aug 2026, 09:30 AM |Updated on 11 Aug 2026, 09:30 AM

Reviewed by

Jubin VScanX News Team

Key Highlights

Concord Drugs reported a 901% YoY surge in standalone net profit to ₹1.11 crore for Q1FY27. Consolidated profits also jumped significantly. The growth outpaced a 33% equity dilution from a preferential share allotment, driving EPS up to ₹0.84.

*this image is generated using AI for illustrative purposes only.

Concord Drugs Limited reported a significant turnaround in profitability for the first quarter of FY27, with standalone net profit surging 901% year-on-year to ₹1.11 crore. The Hyderabad-based pharmaceutical company posted consolidated net profit of ₹1.11 crore for the quarter ended June 30, 2026, compared to ₹0.12 crore in the same period last year. This sharp improvement demonstrates stronger earnings generation even as the company navigated a 33% dilution in its equity share base due to a recent preferential issue.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 10, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors, Pundarikashyam & Associates, issued a limited review report on the financial statements. The results were prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013.

Financial Performance Highlights

Standalone revenue from operations stood at ₹20.89 lakh for the quarter, up from ₹13.38 lakh in Q1FY26. For the full fiscal year ended March 31, 2026, total revenue reached ₹75.85 lakh. Consolidated net sales were slightly higher at ₹20.94 lakh for the current quarter. The company’s paid-up capital remained at ₹13.18 crore, reflecting the inclusion of shares allotted through the preferential issue.

Metric	Standalone Q1FY27 (₹ Lakh)	Standalone Q1FY26 (₹ Lakh)	Change
Revenue from Operations	20.89	13.38	+56%
Total Expenses	19.35	13.23	+46%
Profit Before Tax	1.54	0.15	+927%
Net Profit After Tax	1.11	0.11	+901%
EPS (Basic)	₹0.84	₹0.11	+664%

Consolidated figures mirrored this trend, with profit before tax rising to ₹1.54 lakh from ₹0.16 lakh in the prior year period. Basic earnings per share (EPS) improved to ₹0.84 from ₹0.11 on a standalone basis, and ₹0.85 from ₹0.12 on a consolidated basis.

What the Numbers Show

The most notable aspect of this quarter is the resilience of earnings per share despite significant equity dilution. The company allotted 31,75,000 equity shares at ₹36.50 per share through a preferential issue during the quarter ended March 31, 2026, increasing its weighted average number of equity shares outstanding by over 33%. Typically, such dilution pressures EPS metrics. However, Concord Drugs managed to grow its net profit at a rate that outpaced the expansion of its share base. This indicates that the operational efficiency and revenue growth were sufficient to absorb the dilution impact, delivering higher returns per share to existing investors.

The subsidiary, Proton Remedies Private Limited, contributed ₹0.37 lakh in revenue and ₹0.002 lakh in net profit after tax for the quarter. The consolidated results include the financials of this entity, which were reviewed by their respective independent auditors. The company’s other equity increased to ₹36.45 lakh from ₹35.34 lakh in the previous quarter, reflecting retained earnings accumulation.

Historical Stock Returns for Concord Drugs

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.90%	-1.42%	+6.89%	-12.37%	+45.96%	+165.27%

How will the capital raised from the recent preferential issue be deployed to sustain the 56% revenue growth trajectory in upcoming quarters?

What specific operational strategies or cost-control measures enabled Concord Drugs to offset the 33% equity dilution and achieve a 901% surge in net profit?

Will the subsidiary Proton Remedies Private Limited see increased integration or strategic focus given its current minimal contribution to consolidated profits?

Concord Drugs

View Company Insights

View All News

Concord raises $3M to build agentic execution for media buying

1 min read | Published on 23 Jun 2026, 02:37 PM |Updated on 23 Jun 2026, 02:37 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Concord secured $3 million in seed funding led by A16Z Scout and other investors to advance its agentic media buying platform, Concord Agent. The technology automates campaign management across platforms like DV360 and Meta, offering potential time savings of 70% for users. The company plans to use the capital for product development and expansion in the US and EMEA markets.

*this image is generated using AI for illustrative purposes only.

Concord, the agentic media buying platform, announced a $3 million seed funding round on June 23, 2026, backed by A16Z Scout, Drysdale, Motier Ventures, Better Angle, and industry angels. The capital injection aims to accelerate the development of Concord Agent, a product designed to automate the last manual processes in media buying by turning briefs into live campaigns and managing pacing and optimization across major platforms simultaneously. This funding positions the company to become the execution infrastructure for major media budgets, enabling media buyers to focus on strategy rather than manual operations.

The platform integrates natively with DV360, Meta, YouTube, Amazon DSP, The Trade Desk, TikTok, and Google Ads. It currently serves advertisers within the WPP and Havas agency footprints globally. Early adopters of the technology have reported saving up to 70% of the time previously required for the manual buying loop involving execution, optimization, and reporting.

Investor Validation and Strategic Vision

The round drew validation from prominent figures in the adtech sector, including Rémi Lemonnier, co-founder of Scibids AI, which was acquired by DoubleVerify. Lemonnier described Concord as the missing execution layer of the industry, noting that while the decisioning layer has been built, the execution infrastructure required for the next era of media buying has been absent until now.

Mathias Adam at A16Z Scout characterized Concord's buying agents as the "killer app" for programmatic marketing. He emphasized that the platform automates complex tasks across every major platform simultaneously, representing a foundational shift rather than an incremental fix to the existing programmatic stack.

Leadership and Future Plans

Concord was co-founded by Nathan Venezia, CEO, who previously founded and sold Manadge to iHeartMedia. The leadership team includes Nicolas Cosson as CTO and Antoine Chwalek as Head of Engineering, both of whom previously built the adtech platform at Adot. Venezia stated that the company is building the necessary infrastructure to replace the manual work currently spread across disconnected platforms.

The new funding will be utilized to accelerate product development, expand platform coverage, and grow the team. Concord intends to scale its presence across the US and EMEA regions as it deploys its execution architecture for the intelligence era of media buying.

Historical Stock Returns for Concord Drugs